×
Verrica Pharmaceuticals Receivables 2017-2024 | VRCA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Verrica Pharmaceuticals receivables from 2017 to 2024. Receivables can be defined as the total amount of collectibles for a company
View More
Verrica Pharmaceuticals Receivables 2017-2024 | VRCA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Verrica Pharmaceuticals receivables from 2017 to 2024. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$43.8B
Merck (MKKGY)
$21B
Astellas Pharma (ALPMY)
$20.2B
Sandoz Group AG (SDZNY)
$19.8B
United Therapeutics (UTHR)
$18.3B
Summit Therapeutics (SMMT)
$15.8B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.8B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Jazz Pharmaceuticals (JAZZ)
$7.6B
Orion OYJ (ORINY)
$6.8B
Corcept Therapeutics (CORT)
$6.2B
Ionis Pharmaceuticals (IONS)
$6.2B
Crinetics Pharmaceuticals (CRNX)
$4.9B
PTC Therapeutics (PTCT)
$3.4B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Harrow (HROW)
$1.9B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.7B
ARS Pharmaceuticals (SPRY)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B